Leerink Partners analyst, Michael Schmidt, reiterated his Outperform rating on Incyte (NASDAQ: INCY) after the ESMO 2016 poster for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE